Active Filter(s):
Details:
The company’s first microbial product, “Ensemble No.2” (ENS-002), is designed to rehabilitate the skin microbiome. By taming the pathogenic behaviors of Staphylococcus aureus, ENS-002 may decrease the frequency and severity of eczema flares.
Lead Product(s): ENS-002
Therapeutic Area: Dermatology Product Name: ENS-002
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Safar Partners
Deal Size: $23.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 02, 2022